273BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study

Fecha de inicio: 1 de marzo de 2013

Inclusion Criteria: Histologic confirmation of hematological malignancy consisting of the following leukemias/lymphomas: Mantle cell lymphoma with Ki-67>30% Diffuse Large Cell Lymphoma Burkitts Lymphoma Systemic T Cell Lymphomas Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Recurrence or progression of hematological malignancy after at least 1 prior standard treatment with progression within 6 months from last treatment. No curative treatment option is available. -> 4-weeks since prior chemotherapy or radiation to cellular therapy infusion. (Hydroxyurea may be utilized up to 48 hours prior to initiation of treatment on this protocol). Age equal to or greater than 18 years. Patients with a history of invasive second malignancy unless disease free for > 5 years. Patients must have an expected life expectancy of at least 2 months at the time of initiation of treatment. No active systemic infection. Patients who have relapsed after standard autologous stem cell infusion are eligible as long as they meet all inclusion criteria and no exclusion criteria. These patients must be out more than 6 months from cell infusion to be eligible for enrollment. DLCO > 40% with no symptomatic pulmonary disease. LVEF > 40% by MUGA or echocardiogram. Creatinine < 2.0 mg/dl. Total bilirubin less than 1.5x the upper limit of normal (ULN), AST < 3x ULN. Non-pregnant and willing to use appropriate birth control during the duration of the study period. Exclusion Criteria: Evidence of HIV infection. Any uncontrolled severe, concurrent illness which in the opinion of the treating physician would make this protocol treatment unreasonably hazardous for the patient. Oxygen dependent obstructive pulmonary disease. Failure to demonstrate adequate compliance with medical therapy and follow-up. Significant medical or psychiatric illness that would impair the ability to participate in protocol therapy. For women of reproductive potential, refusal to use effective form of contraception. Previous allogeneic stem cell transplant Patients who have had previous purine analog (fludarabine, pentostatin, 2-CDA) -Patients with chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma, and indolent lymphoma (follicular lymphoma, marginal zone lymphoma) Patients with HLA antibodies to donor HLA type.